Ontology highlight
ABSTRACT:
SUBMITTER: Kandel CE
PROVIDER: S-EPMC4500604 | biostudies-other | 2015
REPOSITORIES: biostudies-other
Kandel Christopher E CE Walmsley Sharon L SL
Drug design, development and therapy 20150707
Dolutegravir is the newest integrase strand transfer inhibitor to be approved for the treatment of human immunodeficiency virus (HIV) infection. Dolutegravir is equivalent or superior to existing treatment regimens in both treatment-naïve and treatment-experienced patients including those with previous raltegravir or elvitegravir failure. The consistent efficacy coupled with excellent tolerability and infrequent drug-drug interactions makes the co-formulation of dolutegravir with two nucleotide ...[more]